Medigen Biotechnology (3176) fair value: what the stock is really worth
We calculate from audited financials what Medigen Biotechnology is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch Medigen Biotechnology for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
60‑month range 23.65 TWD – 86.60 TWD · fair‑value band 13.60 TWD – 124.29 TWD · the 36.50 TWD price screens below the 68.00 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 13, 2026.
Medigen Biotechnology Corp., a biopharmaceutical company, engages in the research and development of new drugs and vaccines, cell therapy, advanced nucleic acid testing, generic drugs, medical beauty, and vaccine-related products in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells.
Show more
Medigen Biotechnology Corp., a biopharmaceutical company, engages in the research and development of new drugs and vaccines, cell therapy, advanced nucleic acid testing, generic drugs, medical beauty, and vaccine-related products in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has completed Phase I clinical trials in combination with esophageal cancer in Japan; is in Phase I clinical trials in combination with immune checkpoint inhibitors (ICI) for patients with esophageal cancer in Japan; and in phase II study in combination with ICI for head and neck cancer, and gastric cancer patients in the United States. Medigen Biotechnology Corp. was founded in 1990 and is headquartered in Taipei, Taiwan.
Stock analysis
Medigen Biotechnology (3176) currently trades at 36.50 TWD, while our model-based Fair Value estimate is 68.00 TWD, implying the stock looks roughly 46.3% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 13.57 TWD per share, and 0 of the 4 models we run sit above the 36.50 TWD price.
Bear case: the Asset-Based group reads lowest at 7.45 TWD, and 4 of the 4 models stay below the price. Evidence for this calculation is low.
Scenario range: 13.60 TWD (bear) to 124.29 TWD (bull), the price of 36.50 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Medigen Biotechnology reported revenue of 1.6B TWD in FY2025 versus 3.9B TWD in FY2021, a compound −20.3%/yr. Reported net income was −109M TWD in FY2025.
Key figures
Market cap 5.1B TWD (≈ $160M) · P/S ratio 3.47 · EPS (TTM) −0.7800 TWD · Dividend yield 1.2% · Net margin −6.9% · Return on equity −9.5% · Return on assets (EBIT) −5.3% · Operating margin −25.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 43 out of 100 (low confidence).
What moves the price
The share trades about 16% below its 52-week high and 30% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at 86%, 3176 screens cheaper than that median.
Fair Value models
Bear 13.60 TWDFair Value 68.00 TWDBull 124.29 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.36/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+15.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.8%
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−148.5% (2020) → −6.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 645 stocks
Beats the industry median on 5/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score52 · Above median
Profitability
Return on assets−3% · Above median
Net margin (TTM)−20% · Below median
Operating margin (TTM)−26% · Bottom 25%
Growth and dividend
Revenue growth−48% · Bottom 25%
Dividend yield (TTM)1.2% · Above median
Balance sheet
Debt / equity0.27× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Medigen Biotechnology Fair Value". https://www.fairvalue-calculator.com/stock/3176
Frequently asked questions
Is Medigen Biotechnology (3176) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of 68.00 TWD versus a price of 36.50 TWD, about +86% upside (undervalued).
What is the fair value of 3176?
Our model-based fair value for Medigen Biotechnology is 68.00 TWD (as of Sep 13, 2026), built from audited fundamentals. The current price: 36.50 TWD.
What is the quality score of 3176?
Medigen Biotechnology has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Medigen Biotechnology (3176)?
Our model-based price target is the fair value of 68.00 TWD (as of Sep 13, 2026) from 4 valuation models. Cautious scenario 13.60 TWD, optimistic scenario 124.29 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Medigen Biotechnology stock forecast for 2026?
Our models put fair value at 68.00 TWD, about +86% upside versus a price of 36.50 TWD (undervalued). Cautious scenario 13.60 TWD, optimistic scenario 124.29 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Medigen Biotechnology (3176)?
Medigen Biotechnology reported trailing-twelve-month revenue of about 1.3B TWD (latest available figure, as of Sep 13, 2026).
Does Medigen Biotechnology pay a dividend?
Medigen Biotechnology currently shows a dividend yield of about 1.24% relative to its recent price (as of Sep 13, 2026).
What is the intrinsic value of Medigen Biotechnology (3176)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Medigen Biotechnology it is 68.00 TWD per share (as of Sep 13, 2026), against a price of 36.50 TWD. It is the blended result of 4 valuation models (cash flow, earnings, asset, dividend).
Is Medigen Biotechnology stock overvalued or undervalued in 2026?
As of Sep 13, 2026, 3176 trades below its calculated fair value: price 36.50 TWD, fair value 68.00 TWD, a gap of about +86% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 3176?
No. The price is what the market pays today (36.50 TWD); the fair value is what the company's own numbers justify (68.00 TWD). For Medigen Biotechnology the two are 31.50 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Medigen Biotechnology worth?
The market values Medigen Biotechnology at about 5.1B TWD (market capitalisation, as of Sep 13, 2026). Per share that is 36.50 TWD; our models calculate a fair value of 68.00 TWD per share.
What do the bullish and bearish scenarios say about 3176?
Our models span a range for Medigen Biotechnology: cautious scenario 13.60 TWD, base 68.00 TWD, optimistic 124.29 TWD per share (as of Sep 13, 2026, price 36.50 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Medigen Biotechnology (3176)?
Balance-sheet figures for Medigen Biotechnology (as of Sep 13, 2026): return on equity −9.5%, debt of 0.27 per unit of equity. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is 3176 from its 52-week high?
Medigen Biotechnology trades at 36.50 TWD, about 16% below its 52-week high of 43.60 TWD and 30% above the low of 28.00 TWD (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of 68.00 TWD is for.
Which stocks are comparable to Medigen Biotechnology?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, BeOne Medicines AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Medigen Biotechnology stock attractive at the current price?
The data as of Sep 13, 2026: price 36.50 TWD, calculated fair value 68.00 TWD (+86%), Quality Score 52/100, from 4 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 3176 calculated?
We run Medigen Biotechnology through 4 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 68.00 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. Medigen Biotechnology currently trades 86 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with Medigen Biotechnology right now?
The model range is unusually wide (13.60 TWD to 124.29 TWD). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (52/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Medigen Biotechnology
How large is the market capitalisation of Medigen Biotechnology (3176)?
The market capitalisation of Medigen Biotechnology is 5.1B TWD (≈ $160M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Medigen Biotechnology (3176)?
The price-to-sales ratio of Medigen Biotechnology is 3.47 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Medigen Biotechnology (3176)?
Earnings per share at Medigen Biotechnology are −0.7800 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Medigen Biotechnology (3176)?
The dividend yield of Medigen Biotechnology is 1.2%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Medigen Biotechnology (3176)?
The net margin of Medigen Biotechnology is −6.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Medigen Biotechnology (3176)?
The return on equity (ROE) of Medigen Biotechnology is −9.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Medigen Biotechnology (3176)?
On an EBIT basis the return on assets of Medigen Biotechnology is −5.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Medigen Biotechnology (3176)?
The operating margin of Medigen Biotechnology is −25.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Medigen Biotechnology (3176)?
Revenue at Medigen Biotechnology is growing −47.6% versus a year earlier (3y avg +14.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Medigen Biotechnology (3176) generate?
The free cash flow of Medigen Biotechnology is −32.9M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Medigen Biotechnology (3176) carry?
The net debt of Medigen Biotechnology is 689M TWD (fiscal year 2023). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Medigen Biotechnology in the live analysis
One click puts Medigen Biotechnology on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
